Obese patients denied knee and hip replacements to slash NHS costs
One third of NHS areas in England and multiple health boards in Wales are blocking patient access based on their body mass index (BMI).
The move, deemed 'unfair' and 'discriminatory', goes against guidance from the National Institute for Care Excellence (Nice), which states BMI shouldn't be used to restrict patients' access to joint replacement surgery.
Patients are instead being told they must lose weight before they are eligible but waiting lists for NHS weight loss programs have ballooned, with some people waiting up to three years to be seen while other services have shut, unable to cope with demand.
The Royal College of Surgeons criticised the policy, saying that denying patients care could cost them their mobility and cause their health to deteriorate, while Tory peer and former health minister James Bethell called on the government to do more to tackle the obesity crisis and end the 'misery for millions'.
More than 64 per cent of adults in England were overweight or living with obesity in 2022-23, up from 63 per cent the year before, the most recent data from the Office for National Statistics shows.
The news comes as 7.4 million people were waiting for NHS treatments in March, while health service leaders have warned they are being forced to cut services to meet tough savings demands from the government.
The shocking revelation of surgery refusals was uncovered in an audit of referral criteria used by NHS bodies in England by the National Institute for Health and Care Research (NIHR).
It found 15 of 42 areas are restricting access to surgery by BMI, while The Independent discovered at least two health boards were doing the same in Wales. Thresholds varied by area, with some limiting access to those with a BMI of less than 35 (patients who are obese) or 40 (severely obese).
Dr Joanna McLaughlin, lead researcher and NIHR clinical lecturer at the University of Bristol, told The Independent that through her research, policymakers, commissioners and surgeons 'acknowledged that NHS financial pressures were a main driver for BMI threshold policy use, and that they didn't have confidence that the policies were based in evidence of health benefits'.
The research also found that NHS weight management support services were 'inadequate' and could not ensure that those excluded from surgery could be supported to lose enough weight. Some patients had resorted to paying privately for surgery.
Dr McLaughlin said: 'The variety in the BMI limits and in the requirements to prove patients have made attempts at weight loss chosen by different ICBs [integrated care boards] highlights the postcode lottery and inequalities created by these policies.'
Several ICBs identified by the study told The Independent that some patients with a high BMI could still access care if they passed an assessment, while others said they would need to prove they were 'fit for surgery'.
But medics told The Independent that BMI should not be used as a sole restrictive measure.
Tim Mitchell, president of the Royal College of Surgeons of England, said losing weight before surgery could reduce the risk of complications, and patients should be supported in this.
However, he said that 'BMI alone should not be a barrier', adding: 'We must not penalise those who are less fit but still eligible for surgery, as this approach is unfair and ignores clinical guidance.'
Mark Bowditch, president of the British Orthopaedic Association, said: 'Losing weight before surgery can be very difficult for people with limited mobility issues.
'Furthermore, obesity is more likely in people from certain socioeconomically deprived areas or ethnic groups, so care must be taken to avoid unintentionally disadvantaging certain patient groups.'
Deborah Alsina, chief executive of charity Versus Arthritis, said: 'We hear heartbreaking stories from people desperate for the pain to stop, and accounts from people who face barriers to access even when they are referred for the surgery they urgently need.
'We frequently hear of people denied a referral, or being taken off the waiting list because of their weight, with body mass index being cited as a rationale. We must make sure this discriminatory practice doesn't become standard.'
Lord Bethell said the row over BMI thresholds for operations showed the NHS 'needs to make a choice' over preventing disease with weight-loss jabs, which cost £100 a month, or to treat obesity-related diseases, such as those that lead to hip operations, which can cost £10,000.
He said the government has a choice to either crack down on 'Junk Food Britain' with a tough food strategy or to give the NHS a lot more money to pay for the consequences of a sick population.
He added: 'It's one or the other. Ducking this choice will cause misery for millions, the bankruptcy of our nation and the end of the Starmer administration.'
A Department of Health and Social Care spokesperson said it expected ICBs to comply with Nice guidance. They added that the department's 'Plan for Change' for the NHS includes rolling out weight loss drugs to 'those who need it most'.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Luceco's (LON:LUCE) investors will be pleased with their decent 42% return over the last three years
Explore Luceco's Fair Values from the Community and select yours Luceco plc (LON:LUCE) shareholders have seen the share price descend 13% over the month. But at least the stock is up over the last three years. However, it's unlikely many shareholders are elated with the share price gain of 27% over that time, given the rising market. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the three years of share price growth, Luceco actually saw its earnings per share (EPS) drop 18% per year. So we doubt that the market is looking to EPS for its main judge of the company's value. Therefore, we think it's worth considering other metrics as well. Do you think that shareholders are buying for the 0.6% per annum revenue growth trend? We don't. While we don't have an obvious theory to explain the share price rise, a closer look at the data might be enlightening. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Luceco will earn in the future (free profit forecasts). What About Dividends? It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Luceco, it has a TSR of 42% for the last 3 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. A Different Perspective While the broader market gained around 22% in the last year, Luceco shareholders lost 11% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Luceco that you should be aware of. Luceco is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
More than 100 civil servants set to be cut from security vetting and Cobra teams
More than a hundred jobs could be cut from the organisation in charge of vetting people for security clearance as the Government looks to slim down the Civil Service. The Cabinet Office has proposed reducing the staff at UK Security Vetting (UKSV) to 780 full-time roles, down from its current level of just under 900, the PA news agency understands. Further cuts have also been proposed for the teams supporting the Government's emergency Cobra committee, including the number of staff working on chemical, biological and radiological threats. PCS union chief Fran Heathcote warned that the cuts would 'compromise key Government functions, including those critical to national security and emergency preparedness'. The process is understood to be still ongoing and no final decisions on job cuts have been made. The proposed cuts are part of wider plans to reduce the number of civil servants working for the Cabinet Office by 2,100 as part of efforts to cut the overall cost of government by 15%. Most of the cuts are expected to come through voluntary redundancy or by not replacing people who leave, while other civil servants will be redeployed elsewhere. A source familiar with the proposals told PA that the Cabinet Office had proposed cutting around 110 jobs from UKSV, which vets people for sensitive roles including in the Ministry of Defence and the Foreign Office, as well as conducting security checks on staff applying for parliamentary passes. UKSV was heavily criticised by the National Audit Office in 2023 over delays carrying out checks that, the watchdog said, risked hampering work on national security. Writing in Civil Service World last year, UKSV's chief executive Trish Deghorn said the organisation had managed to turn itself around since then, in part due to increased staffing levels. A source told PA that the Cabinet Office had argued that back-office staff working on UKSV's recovery were no longer required and the organisation's headcount could now be cut. The source also told PA that around 30 jobs were proposed to be cut from the teams supporting Cobra after a merger of Cabinet Office directorates working on crisis response and resilience. These include cutting three of the 10 staff working on chemical, biological and radiological threats, although the team will continue to exist. Fran Heathcote, general secretary of the PCS union, said: 'We warned from the outset that plans for job cuts at the Cabinet Office failed to distinguish between back-office and frontline roles. 'It is now evident that these cuts will undermine the delivery of essential public services and compromise key government functions, including those critical to national security and emergency preparedness. 'PCS will continue to stand firmly with our members in opposing these damaging cuts. We will defend their job security and the vital work they do to keep the country running safely and effectively.' Alex Burghart, the Conservative shadow chancellor of the duchy of Lancaster, said: 'While Labour let the welfare state balloon to £100 billion per year, handing out billion-pound bungs to their union paymasters whilst funnelling money into diversity jobs, it beggars belief they are cutting back on our national security and emergency infrastructure. 'As always for Labour, it's party first, country second.' A UK Government spokesperson said: 'We don't routinely comment on national security staffing. 'More broadly, we are making the department more strategic, specialist and smaller, helping existing teams better serve the public and deliver the plan for change.'
Yahoo
an hour ago
- Yahoo
Up 10% in a week, is this FTSE 100 stock set to be the comeback story of 2025?
Diageo (LSE:DGE) shares are up 10% since the firm released its full-year earnings on Monday (4 August). I own shares in the FTSE 100 drinks company and I thought the results were… fine. Importantly though, both the firm's results and its forward guidance were ahead of analyst expectations. And a lot of the time, this is what makes share prices move in the short term. The results In the 12 months leading up to 30 June, Diageo reported organic sales growth of 1.7%, while earnings per share fell 0.7% due to increased investments in facilities. Neither of these numbers are particularly inspiring, but both are ahead of what analysts had been expecting. And that's part of the reason the stock's responded positively. The company's forward-looking guidance was much more positive. Diageo expects similar sales growth in 2026, but is looking to make a series of cost cuts, which should lead to 5% profit growth. This is very clearly better than investors had anticipated, but it's worth keeping things in context. And to be fair, the market's doing this – the stock's still down 22% since the start of the year. Not the end Until February, Diageo's official medium-term guidance was for organic revenue growth to be in the region of 6%. And with the firm set to achieve 1.7% again next year, that seems a long way off. Furthermore, while the plan to reduce costs might be a good one, it's not really a strategy for long-term growth. There's only so much cost-cutting to boost profits any business can do. After the Second Battle of El Alamein, Winston Churchill famously said: 'This is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning'. That's pretty much my view on Diageo at the moment. The business is a long way off where I might have hoped it would be, but it is – at least – starting to show signs of arresting the decline. Valuation Diageo's a fascinating stock. When things are going well, investors focus on its obvious strengths, but when they start to go wrong, the market sees nothing but threats. The truth – as is often the case – is probably somewhere in the middle. The FTSE 100 firm's brands and scale are a genuine strength, but GLP-1 drugs are also a very real challenge. That means the trick when it comes to buying the stock is to try and work out when investors are pessimistic and focusing on the negatives. That's when the shares trade at attractive prices. Despite the share price climbing 10% in the last week, I think this is still the case. A price-to-earnings (P/E) ratio of 16 is towards the lower end of where the stock has traded over the last five years. The comeback story of 2025? Diageo's set out a clear agenda for growth over the next 12 months. And this was definitely a positive surprise for the stock market, which is why the share price has jumped. I don't think the stock's going to be the comeback story of 2025. But I'm optimistic this might be the year when the company manages to stop the downturn of the last few years. I feel it's worth watching. The post Up 10% in a week, is this FTSE 100 stock set to be the comeback story of 2025? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has positions in Diageo Plc. The Motley Fool UK has recommended Diageo Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data